AU2022222756A1 - Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins - Google Patents

Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins Download PDF

Info

Publication number
AU2022222756A1
AU2022222756A1 AU2022222756A AU2022222756A AU2022222756A1 AU 2022222756 A1 AU2022222756 A1 AU 2022222756A1 AU 2022222756 A AU2022222756 A AU 2022222756A AU 2022222756 A AU2022222756 A AU 2022222756A AU 2022222756 A1 AU2022222756 A1 AU 2022222756A1
Authority
AU
Australia
Prior art keywords
cyclodextrin
cholesterol
beta
hydroxypropyl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022222756A
Other languages
English (en)
Inventor
Jason CAMM
Henricus Duckers
Diana KERWIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beren Therapeutics PBC
Original Assignee
Beren Therapeutics PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics PBC filed Critical Beren Therapeutics PBC
Publication of AU2022222756A1 publication Critical patent/AU2022222756A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2022222756A 2021-02-18 2022-02-18 Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins Abandoned AU2022222756A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150908P 2021-02-18 2021-02-18
US63/150,908 2021-02-18
PCT/US2022/017090 WO2022178318A1 (en) 2021-02-18 2022-02-18 Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins

Publications (1)

Publication Number Publication Date
AU2022222756A1 true AU2022222756A1 (en) 2023-09-14

Family

ID=82800248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022222756A Abandoned AU2022222756A1 (en) 2021-02-18 2022-02-18 Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins

Country Status (5)

Country Link
US (2) US20220260597A1 (https=)
EP (1) EP4294403A4 (https=)
JP (1) JP2024509376A (https=)
AU (1) AU2022222756A1 (https=)
WO (1) WO2022178318A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024053812A1 (en) * 2022-09-08 2024-03-14 Renatus Inc. Methods for the treatment of chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
AU773385B2 (en) * 1999-05-14 2004-05-27 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
WO2001055301A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2553710A1 (en) * 2004-01-15 2005-07-28 Aska Pharmaceutical Co., Ltd. Abca1 stabilizer
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
WO2011116245A2 (en) * 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
EP3405501B1 (en) * 2016-01-21 2023-11-15 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
CN107854448A (zh) * 2017-11-06 2018-03-30 广州市桐晖药业有限公司 一种烟酸片及其制备方法
EP3870181B1 (en) * 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
KR20230096975A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법

Also Published As

Publication number Publication date
US20230375576A1 (en) 2023-11-23
EP4294403A4 (en) 2024-12-11
JP2024509376A (ja) 2024-03-01
WO2022178318A1 (en) 2022-08-25
EP4294403A1 (en) 2023-12-27
US20220260597A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
US20230330133A1 (en) Methods for the treatment of cholesterol crystal embolization with cyclodextrins
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US20140200204A1 (en) Combinations of corroles and statins
WO2002085117A1 (en) Methods and compositions for preventing and treating septic shock and endotoxemia
US20130005824A1 (en) Treatment of ischemic tissue
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
US20240398849A1 (en) Methods for the treatment of hypertriglyceridemia with cyclodextrins
JP2000511550A (ja) リポタンパク質（ａ）の血漿水準を低下させるための薬剤の製造のための、ラロキシフェン及び類縁化合物の使用
TWI756537B (zh) 金奈米團簇於治療高膽固醇血症或與高膽固醇血症相關之疾病的用途
US20040006129A1 (en) Prevention or treatment of abnormal lipoprotein, atherosclerosis and cholestasis

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period